Helius Medical ($HSDT) PoNS Trial Shows Promise for Stroke Gait Deficits
Helius Medical Technologies, Inc. (HSDT) announced a positive outcome from the PoNS Stroke Registrational Program supporting a planned FDA submission seeking an indication for...
Telomir Pharmaceuticals, Inc. ($TELO) Highlights Telomir-1’s Superior Efficacy Over Standard Cancer Drugs
Telomir Pharmaceuticals, Inc. (TELO) revealed groundbreaking preclinical results demonstrating Telomir-1’s power to reverse epigenetic gene silencing in aggressive human prostate cancer cells, outperforming Paclitaxel...
Viatris Inc. ($VTRS) Announces Phase 3 Blepharitis Study Misses Key Goal
Viatris Inc. (VTRS) reported that its Phase 3 study evaluating pimecrolimus 0.3% ophthalmic ointment for blepharitis did not achieve the primary endpoint of complete...
U.S. Patent Awarded to Nuwellis, Inc. ($NUWE) for Extracorporeal Device
Nuwellis, Inc. (NUWE) has secured U.S. Patent No. 12,357,734 for its “Extracorporeal Blood Filtering Machine and Methods,” officially granted on July 15, 2025, enhancing...
Celcuity Inc. ($CELC) Gains Patent Protection for Breast Cancer Drug Gedatolisib
Celcuity Inc. (CELC) has secured U.S. Patent No. 12,350,276, protecting the clinical dosing regimen of its lead drug candidate, gedatolisib, for ER+/HER2- breast cancer...
Milestone Pharmaceuticals Inc. ($MIST) Advances CARDAMYST™ Nasal Spray FDA Review
Milestone® Pharmaceuticals Inc. (MIST) announced that the FDA has accepted for review the company’s response to the Complete Response Letter for CARDAMYST™ (etripamil) nasal...
Cogent Biosciences ($COGT) Achieves Significant Improvement in Mastocytosis Study
Cogent Biosciences, Inc. (COGT) announced positive top-line results from the registration-directed Part 2 of the SUMMIT clinical trial of bezuclastinib in patients with non-advanced...
FDA Approves EKTERLY by KalVista ($KALV) as First Oral On-Demand HAE Treatment
KalVista Pharmaceuticals, Inc. (KALV) announced FDA approval of EKTERLY, a novel plasma kallikrein inhibitor, for treating acute hereditary angioedema attacks in patients aged 12...
APGE’s APG777 Shows Promise in Treating Moderate-to-Severe Atopic Dermatitis
Apogee Therapeutics, Inc. (APGE) announced positive 16-week data from Part A of the Phase 2 APEX clinical trial of APG777, a potential best-in-class anti-IL-13...
Regeneron Pharmaceuticals, Inc. ($REGN) Secures FDA Nod for Lynozyfic™ Targeting Relapsed Multiple Myeloma
Regeneron Pharmaceuticals, Inc. (REGN) announced that the U.S. Food and Drug Administration has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult patients with...